key: cord-0018480-le1kuznu
authors: Bonjour, Maxime; Charvat, Hadrien; Franco, Eduardo L; Piñeros, Marion; Clifford, Gary M; Bray, Freddie; Baussano, Iacopo
title: Global estimates of expected and preventable cervical cancers among girls born between 2005 and 2014: a birth cohort analysis
date: 2021-04-15
journal: Lancet Public Health
DOI: 10.1016/s2468-2667(21)00046-3
sha: e1a4b5f8d89f854daddc7179ccdb82a62c833a17
doc_id: 18480
cord_uid: le1kuznu

BACKGROUND: WHO has launched an initiative aiming to eliminate cervical cancer as a public health problem. Elimination is a long-term target that needs long-lasting commitment. To support local authorities in implementing human papillomavirus (HPV) vaccination, we provide regional and country-specific estimates of cervical cancer burden and the projected impact of HPV vaccination among today's young girls who could develop cervical cancer if not vaccinated. METHODS: The expected number of cervical cancer cases in the absence of vaccination among girls born between 2005 and 2014 was quantified by combining age-specific incidence rates from GLOBOCAN 2018 and cohort-specific mortality rates by age from UN demographic projections. Preventable cancers were estimated on the basis of HPV prevalence reduction attributable to vaccination and the relative contribution of each HPV type to cervical cancer incidence. We assessed the number of cervical cancer cases preventable through vaccines targeting HPV types 16 and 18, with and without cross-protection, and through vaccines targeting HPV types 16, 18, 31, 33, 45, 52, and 58. FINDINGS: Globally, without vaccination, the burden of cervical cancer in these birth cohorts is expected to reach 11·6 million (95% uncertainty interval 11·4–12·0) cases by 2094. Approximately 75% of the burden will be concentrated in 25 countries mostly located in Africa and Asia, where the future number of cases is expected to increase manyfold, reaching 5·6 million (5·4–6·0) cases in Africa and 4·5 million (4·4–4·6) cases in Asia. Worldwide immunisation with an HPV vaccine targeted to HPV types 16 and 18, with cross-protection against HPV types 31, 33, and 45, could prevent about 8·7 million (8·5–9·0) cases. INTERPRETATION: Detailed estimates of the increasing burden of cervical cancer and projected impact of HPV vaccination is of immediate relevance to public health decision makers. Shifting the focus of projections towards recently born girls who could develop cervical cancer if not vaccinated is fundamental to overcome stakeholders' hesitancy towards HPV vaccination. FUNDING: Bill & Melinda Gates Foundation, Canadian Institutes of Health Research.

Derivation of the formula for estimating the contribution to the cumulative incidence of cervical cancer for a particular age group taking account of the competing risk of dying from any cause before being diagnosed with cervical cancer.

For a given cohort of women, the expected cumulative number of cervical cancers between age 15 and 79 years in the absence of vaccination was calculated by using 5-year age group-specific cervical cancer incidence rate projections from the Global Cancer Observatory (GLOBOCAN) (http://gco.iar.fr) project, 1,2 and 5-year age groupspecific mortality rates were obtained from United Nations, Department of Economic and Social Affairs, Population Division. 3 Let 0 be the age group 15-19 years, …, 12 be the age group 75-79 years. Let us denote by and respectively cervical cancer incidence rate and mortality rate, both assumed to be piecewise constant functions on each five-year age group. That is, for = 0, … , 12, , and , denote respectively the constant -specific cervical cancer incidence and mortality rates. Let us also designate by and respectively the lower and upper bound of age interval , with for > 0, = −1 . Then, the survival free from event (i.e., cervical cancer diagnosis or death) by age for a cohort of women aged 15 at the start of follow-up can be calculated according 

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods

United Nations Department of Economic and Social Affairs Population Division

Human papillomavirus types in 115,789 HPV-positive women: A metaanalysis from cervical infection to cancer

Saudi Arabia

Saudi Arabia